Related Experiment Video
Updated: Aug 24, 2025
04:56
Author Spotlight: Deciphering Coagulation Disorders in Traumatic Brain Injury Patients
Published on: August 4, 2023
831
Association between Thrombin Generation and Clinical Characteristics in COVID-19 Patients
Omri Cohen1,2,3, Nitsan Landau2,4, Einat Avisahai1,2
1National Hemophilia Center and Institute of Thrombosis and Hemostasis, Sheba Medical Center, Ramat Gan, Israel.
Acta Haematologica
|October 23, 2022
Summary
Thrombin generation (TG) capacity in COVID-19 patients did not correlate with disease severity. However, endogenous thrombin potential (ETP) showed a correlation with the sepsis-induced coagulopathy (SIC) score.
Area of Science:
- Hematology
- Infectious Diseases
- Critical Care Medicine
Background:
- Coronavirus disease 2019 (COVID-19) is linked to coagulopathy and thrombosis.
- The relationship between thrombin generation (TG) capacity, COVID-19 severity, and outcomes requires further elucidation.
Purpose of the Study:
- To investigate the correlation of TG capacity with disease severity scores (SOFA, SIC) and clinical outcomes in hospitalized COVID-19 patients.
- To assess the impact of anticoagulant therapy on TG parameters.
Main Methods:
- Plasma samples from hospitalized COVID-19 patients were analyzed for TG parameters.
- Correlation analysis was performed between TG parameters, SOFA scores, SIC scores, and clinical outcomes.
- TG parameters were compared between patients receiving different doses of anticoagulant therapy and healthy controls.
Main Results:
- No significant correlation was found between TG parameters and SOFA scores or mortality.
- Patients receiving higher anticoagulant doses showed increased lag time, reduced ETP, and lower peak height.
- ETP demonstrated a significant correlation with the SIC score (p = 0.038).
Conclusions:
- TG capacity is not associated with COVID-19 disease severity.
- A notable correlation exists between ETP and the SIC score, warranting further investigation.
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
849
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
849
01:20Venous Thrombosis II: Clinical Manifestations and Diagnostic Studies
28
The key difference between Superficial Vein Thrombosis (SVT) and Deep Vein Thrombosis (DVT) lies in their location and severity.Clinical ManifestationsSVT typically presents with localized pain, tenderness, and redness along the course of a superficial vein, often accompanied by a palpable, cord-like structure under the skin. This condition is usually less dangerous than DVT but can be uncomfortable and may lead to complications such as cellulitis or, rarely, a clot extension into the deep...
28
01:29Venous Thrombosis III: Interprofessional Care
18
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
18
01:30Venous Thrombosis I: Introduction
29
Venous thrombosis, the most common disorder of the veins, involves the formation of a thrombus or blood clot associated with vein inflammation. It can be classified as either superficial vein thrombosis or deep vein thrombosis.Superficial Vein Thrombosis: This involves the formation of a thrombus in a superficial vein, usually the greater or lesser saphenous vein. Though less severe than deep vein thrombosis (DVT), SVT can lead to complications if untreated.Deep Vein Thrombosis (DVT): This...
29
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
1.3K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
1.3K
01:20Extrinsic and Intrinsic Pathways of Hemostasis
8.8K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
8.8K